- Home
- ATER vs LPTX Comparison
ATER vs LPTX Comparison
Compare ATER & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATER
- LPTX
- Stock Information
- Founded
- ATER 2014
- LPTX 2011
- Country
- ATER United States
- LPTX United States
- Employees
- ATER N/A
- LPTX N/A
- Industry
- ATER Home Furnishings
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ATER Consumer Discretionary
- LPTX Health Care
- Exchange
- ATER Nasdaq
- LPTX Nasdaq
- Market Cap
- ATER 10.3M
- LPTX 11.1M
- IPO Year
- ATER N/A
- LPTX N/A
- Fundamental
- Price
- ATER $1.07
- LPTX $0.62
- Analyst Decision
- ATER
- LPTX Hold
- Analyst Count
- ATER 0
- LPTX 1
- Target Price
- ATER N/A
- LPTX N/A
- AVG Volume (30 Days)
- ATER 130.3K
- LPTX 7.8M
- Earning Date
- ATER 11-10-2025
- LPTX 11-12-2025
- Dividend Yield
- ATER N/A
- LPTX N/A
- EPS Growth
- ATER N/A
- LPTX N/A
- EPS
- ATER N/A
- LPTX N/A
- Revenue
- ATER $85,668,000.00
- LPTX N/A
- Revenue This Year
- ATER N/A
- LPTX N/A
- Revenue Next Year
- ATER $7.48
- LPTX N/A
- P/E Ratio
- ATER N/A
- LPTX N/A
- Revenue Growth
- ATER N/A
- LPTX N/A
- 52 Week Low
- ATER $0.90
- LPTX $0.22
- 52 Week High
- ATER $3.50
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- ATER 48.70
- LPTX 58.59
- Support Level
- ATER $1.04
- LPTX $0.57
- Resistance Level
- ATER $1.12
- LPTX $0.78
- Average True Range (ATR)
- ATER 0.08
- LPTX 0.13
- MACD
- ATER -0.00
- LPTX 0.00
- Stochastic Oscillator
- ATER 20.00
- LPTX 44.57
About ATER Aterian Inc.
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products and, consumer electronics. It has various owned and operates brands, including HomeLabs, Squatty Potty, Healing Solutions, PurSteam, and others. The company generates revenue through the online sales of various consumer products that are sold online.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.